{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002861","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.616710+00:00","generated_at":"2026-05-16T10:52:37.757266+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook","bullets":["Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.","Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.","Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).","Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002861","json":"https://secwatch.observer/filing/0001104659-26-002861.json","markdown":"https://secwatch.observer/filing/0001104659-26-002861.md","text":"https://secwatch.observer/filing/0001104659-26-002861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/0001104659-26-002861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/tm262952d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:37.757266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}